WINTON GROUP Ltd Trims Holdings in United Therapeutics Corporation $UTHR

Key Points

• WINTON GROUP Ltd cut its United Therapeutics stake by 82.4% in the second quarter, selling 10,752 shares and retaining 2,292 shares worth approximately $1.24 million.
• United Therapeutics reported quarterly EPS of $7.27, above estimates of $6.86, but revenue fell 1.9% year over year to $783.3 million, below expectations. The stock opened at $497.11, versus a consensus analyst target of $646 and a “Moderate Buy” rating.
• Institutional investors own 94.08% of the company, while insiders sold about $191.7 million in shares over the past 90 days, including sales by the CEO and an executive vice president.

WINTON GROUP Ltd reduced its holdings in shares of United Therapeutics Corporation (NASDAQ:UTHR - Free Report) by 82.4% during the 2nd quarter, according to its most recent 13F filing with the SEC. The fund owned 2,292 shares of the biotechnology company's stock after selling 10,752 shares during the period. WINTON GROUP Ltd's holdings in United Therapeutics were worth $1,242,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently bought and sold shares of the business. California State Teachers Retirement System increased its position in United Therapeutics by 55,526.2% in the 2nd quarter. California State Teachers Retirement System now owns 33,288,952 shares of the biotechnology company's stock valued at $18,036,953,000 after acquiring an additional 33,229,108 shares during the period. BlackRock Inc. purchased a new stake in shares of United Therapeutics during the second quarter worth approximately $2,868,735,000. Avoro Capital Advisors LLC raised its stake in shares of United Therapeutics by 17.3% during the fourth quarter. Avoro Capital Advisors LLC now owns 2,606,060 shares of the biotechnology company's stock worth $1,269,803,000 after purchasing an additional 383,838 shares during the last quarter. Wellington Management Group LLP lifted its holdings in shares of United Therapeutics by 74.5% during the fourth quarter. Wellington Management Group LLP now owns 2,441,492 shares of the biotechnology company's stock worth $1,189,617,000 after purchasing an additional 1,042,711 shares during the period. Finally, AQR Capital Management LLC grew its position in United Therapeutics by 29.9% in the 4th quarter. AQR Capital Management LLC now owns 1,281,699 shares of the biotechnology company's stock valued at $624,508,000 after buying an additional 295,221 shares during the last quarter. 94.08% of the stock is currently owned by institutional investors and hedge funds.

United Therapeutics Price Performance

Shares of UTHR stock opened at $497.11 on Monday. United Therapeutics Corporation has a fifty-two week low of $396.12 and a fifty-two week high of $609.35. The business has a fifty day simple moving average of $520.91 and a 200-day simple moving average of $540.76. The stock has a market cap of $21.32 billion, a P/E ratio of 17.79, a P/E/G ratio of 2.49 and a beta of 0.56.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last issued its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $7.27 EPS for the quarter, beating analysts' consensus estimates of $6.86 by $0.41. United Therapeutics had a net margin of 41.56% and a return on equity of 20.18%. The firm had revenue of $783.30 million for the quarter, compared to analysts' expectations of $804.65 million. During the same period in the prior year, the company earned $6.41 EPS. The firm's revenue was down 1.9% on a year-over-year basis. On average, sell-side analysts anticipate that United Therapeutics Corporation will post 26.21 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities analysts have commented on the stock. Morgan Stanley set a $515.00 price objective on shares of United Therapeutics in a research report on Thursday, August 6th. Royal Bank Of Canada dropped their price target on shares of United Therapeutics from $704.00 to $677.00 and set an "outperform" rating on the stock in a research note on Thursday, August 6th. Bank of America reduced their price objective on shares of United Therapeutics from $620.00 to $613.00 and set a "neutral" rating for the company in a research report on Friday, July 10th. Weiss Ratings lowered United Therapeutics from a "buy (b)" rating to a "buy (b-)" rating in a report on Thursday, August 27th. Finally, TD Cowen reissued a "buy" rating on shares of United Therapeutics in a research note on Thursday, May 21st. Eleven equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $646.00.

Insider Activity

In related news, EVP Paul A. Mahon sold 8,300 shares of United Therapeutics stock in a transaction that occurred on Thursday, September 3rd. The stock was sold at an average price of $482.03, for a total transaction of $4,000,849.00. Following the completion of the transaction, the executive vice president directly owned 45,172 shares in the company, valued at $21,774,259.16. The trade was a 15.52% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Martine A. Rothblatt sold 9,500 shares of the company's stock in a transaction that occurred on Thursday, September 10th. The shares were sold at an average price of $502.35, for a total value of $4,772,325.00. Following the completion of the sale, the chief executive officer directly owned 324,443 shares in the company, valued at approximately $162,983,941.05. The trade was a 2.84% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 364,575 shares of company stock worth $191,659,133 in the last ninety days. Insiders own 8.60% of the company's stock.

United Therapeutics Company Profile

United Therapeutics Corporation is a biotechnology company focused on developing and commercializing therapies for serious and life-threatening conditions, with a primary emphasis on pulmonary arterial hypertension (PAH). The company's products are designed to improve pulmonary blood flow and reduce the effects of this progressive disease.

United Therapeutics' PAH portfolio includes Remodulin (treprostinil) injection, Orenitram (treprostinil) extended-release tablets, and Tyvaso (treprostinil), which is available as an inhalation solution and as the Tyvaso DPI dry-powder inhaler.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.